Indirect Homogeneous Mobility Shift Assay for Biologic Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tests lack accuracy for measuring the levels of biologics such as vedolizumab and ustekinumab in patients, which hinders effective treatment management for inflammatory bowel diseases like Crohn's disease and ulcerative colitis, as existing methods fail to precisely monitor drug efficacy and toxicity.
Innovation Solution
The development of novel indirect homogeneous mobility shift assays using size exclusion chromatography to detect and quantify biologics by forming complexes with unlabeled and labeled antigens, allowing for precise measurement of biologic levels in patient samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing diagnostic tests are used to measure biologic levels, then the testing process can be performed, but the measurement accuracy is insufficient for effective treatment management
Solution Approach 1:
The patent employs an intermediary antigen that binds to the biologic antibody, allowing indirect detection through a measurable complex formation. This intermediary approach enables accurate quantification of biologic levels in patient samples by measuring the antigen-antibody complex rather than the biologic directly, thereby resolving the contradiction between performability and measurement accuracy.
Solution Approach 2:
The patent replaces traditional mechanical or direct detection methods with a biochemical complex formation system. By substituting direct biologic detection with an indirect assay based on antigen-antibody complex formation and size exclusion chromatography, the system achieves superior measurement precision while maintaining treatment management reliability.
2Ease of manufacture
If direct detection methods are used for biologics, then the assay can be performed, but the complexity increases due to the need to handle complex antigens
Solution Approach 1:
The patent uses a soluble antigen as an intermediary that simplifies the detection process. Instead of directly handling complex membrane-bound antigens, the assay employs a soluble form that can be easily incorporated into the assay system, thereby reducing device and protocol complexity while maintaining ease of manufacture.
Solution Approach 2:
The patent changes the physical state and solubility parameters of the antigen from membrane-bound to soluble form. This parameter change enables the antigen to be easily handled in solution-based assays, significantly simplifying assay development and manufacturing while reducing the complexity of antigen handling requirements.
3Measurement precision
If conventional assay methods are used, then the testing can be completed, but the sensitivity is insufficient for monitoring drug efficacy and toxicity
Solution Approach 1:
The patent employs an intermediary antigen-antibody complex formation system that enhances detection sensitivity. By measuring the complex formation rather than the biologic directly, the assay achieves the sensitivity required for monitoring drug efficacy and toxicity, thereby improving treatment optimization speed without compromising productivity.
Solution Approach 2:
The patent substitutes conventional detection mechanisms with a biochemical complex-based detection system. This substitution enables sensitive monitoring of low concentrations of biologic drugs, improving measurement precision for efficacy and toxicity assessment while maintaining efficient treatment optimization workflows.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These assays provide accurate and sensitive measurements of biologic levels, enabling improved therapeutic management, reduced toxicity, and optimized treatment decisions for patients receiving biologic therapy.
Implementation Method 1
subjecting the unlabeled and labeled complexes to size exclusion chromatography to separate the unlabeled and labeled complexes from free labeled biologic
Implementation Method 2
contacting the sample with an unlabeled soluble antigen that binds to the biologic to form an unlabeled complex between the antigen and the biologic
Implementation Method 3
contacting the sample from step (a) with a labeled form of the biologic to form a labeled complex between the antigen and the labeled biologic
Data Source
AI summary
The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or level of biologics that target complex or large antigens including cell surface proteins, transmembrane proteins, heavily glycosylated proteins, and multimeric proteins, as well as antigens that cannot be purified, impure antigens, and partially or substantially purified antigens. The present invention also provides isolated soluble α4β7 integrin heterodimers and isolated soluble IL-12p40 monomers that are suitable for use in the indirect assays described herein.